{
    "id": 23444,
    "fullName": "PTPN11 E76A",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "PTPN11 E76A lies within the SH2 domain 1 of the Ptpn11 protein (UniProt.org). E76A is predicted to confer a gain of function to the Ptpn11 protein, as demonstrated by increased activity of protein tyrosine phosphatase in cell culture (PMID: 15834506).",
            "references": [
                {
                    "id": 4292,
                    "pubMedId": 15834506,
                    "title": "Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15834506"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5781,
        "geneSymbol": "PTPN11",
        "terms": [
            "PTPN11",
            "BPTP3",
            "CFC",
            "JMML",
            "METCDS",
            "NS1",
            "PTP-1D",
            "PTP2C",
            "SH-PTP2",
            "SH-PTP3",
            "SHP2"
        ]
    },
    "variant": "E76A",
    "createDate": "06/21/2016",
    "updateDate": "01/31/2020",
    "referenceTranscriptCoordinates": {
        "id": 96187,
        "transcript": "NM_002834",
        "gDna": "chr12:g.112450407A>C",
        "cDna": "c.227A>C",
        "protein": "p.E76A",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16048,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) in combination with SHP099 did not inhibit growth of pancreatic ductal adenocarcinoma harboring KRAS G12D and expressing PTPN11 E76A in culture (PMID: 29808009).",
            "molecularProfile": {
                "id": 31390,
                "profileName": "KRAS G12D PTPN11 E76A"
            },
            "therapy": {
                "id": 7400,
                "therapyName": "Selumetinib + SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14154,
                    "pubMedId": 29808009,
                    "title": "Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29808009"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16047,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) in combination with GS-493 inhibited growth of pancreatic ductal adenocarcinoma harboring KRAS G12D and expressing PTPN11 E76A in culture (PMID: 29808009).",
            "molecularProfile": {
                "id": 31390,
                "profileName": "KRAS G12D PTPN11 E76A"
            },
            "therapy": {
                "id": 7864,
                "therapyName": "GS-493 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14154,
                    "pubMedId": 29808009,
                    "title": "Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29808009"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 24133,
            "profileName": "PTPN11 E76A",
            "profileTreatmentApproaches": [
                {
                    "id": 9543,
                    "name": "SHP2 Inhibitor",
                    "profileName": "PTPN11 E76A"
                }
            ]
        },
        {
            "id": 31390,
            "profileName": "KRAS G12D PTPN11 E76A",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 96188,
            "transcript": "NM_080601",
            "gDna": "chr12:g.112450407A>C",
            "cDna": "c.227A>C",
            "protein": "p.E76A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 96189,
            "transcript": "XM_006719526",
            "gDna": "chr12:g.112450407A>C",
            "cDna": "c.227A>C",
            "protein": "p.E76A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 96187,
            "transcript": "NM_002834",
            "gDna": "chr12:g.112450407A>C",
            "cDna": "c.227A>C",
            "protein": "p.E76A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}